• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Chlorthalidone is not superior to hydrochlorothiazide in preventing hypertension-related cardiovascular events

byDavid XiangandKiera Liblik
January 4, 2023
in Cardiology, Chronic Disease, Emergency
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with hypertension who received chlorthalidone did not have a lower occurrence of adverse cardiovascular outcomes compared to patients who received hydrochlorothiazide.

2. Patients who received chlorthalidone did not have a lower occurrence of non-cancer-related deaths than patients who received hydrochlorothiazide. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Thiazide diuretics are often first-line antihypertensive agents used to prevent adverse cardiovascular outcomes in patients with hypertension. Early studies have suggested that chlorthalidone is superior to hydrochlorothiazide in patients with hypertension. Though, recent studies have shown similar efficacy between the two medications. However, there is a gap in knowledge as to understanding whether chlorthalidone, as compared with hydrochlorothiazide reduces the risk of major cardiovascular disease outcomes and non–cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline. Overall, this study found that chlorthalidone did not lead to a lower incidence of major cardiovascular outcomes or non–cancer-related deaths than hydrochlorothiazide in patients with hypertension at doses commonly used in clinical practice. This study was limited by being open-label, which included patients who were assigned to the chlorthalidone group that switched back to hydrochlorothiazide. Nevertheless, these study’s findings are significant, as they demonstrate that chlorthalidone is not superior to hydrochlorothiazide in lowering major cardiovascular outcomes or non-cancer-related deaths in patients with hypertension.

Click to read the study in NEJM

Relevant Reading: Thiazide-like versus Thiazide Diuretics — Finally, an Answer?

In-Depth [pragmatic open-label trial]: This multicenter, pragmatic, open-label trial was conducted by the Department of Veteran Affairs healthcare system. Patients who were at least 65 years of age and had hypertension and an active prescription for hydrochlorothiazide at a dose of 25 or 50mg per day were eligible for the study. Patients who were taking blood-pressure medication that contained hydrochlorothiazide combined with other agents were excluded from the study. The primary outcome measured was the first occurrence of a composite outcome consisting of a nonfatal cardiovascular disease event or non–cancer-related death, assessed in a time-to-event analysis. Nonfatal cardiovascular disease events were nonfatal myocardial infarction, stroke, hospitalization for heart failure, or urgent coronary revascularization for unstable angina. Outcomes of the primary analysis were assessed via unadjusted log-rank tests that were stratified according to the Veteran Affairs healthcare system. Based on the primary analysis, with a median follow-up of 2.4 years, there was little difference in the occurrence of primary-outcome events between the chlorthalidone group (702 patients [10.4%]) and the hydrochlorothiazide group (675 patients [10.0%]) (hazard ratio, 1.04; 95% confidence interval, 0.94 to 1.16). There were no between-group differences in the occurrence of any of the components of the primary outcome. The incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%; p<0.001). Overall, this study demonstrates that patients receiving chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients receiving hydrochlorothiazide.

RELATED REPORTS

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

Over-the-scope clips superior to standard treatment of nonvariceal upper GI bleeding

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood pressurecardiologycardiovascular diseasechlorthalidonechronic diseaseemergencyhydrochlorothiazidehypertensionmajor adverse cardiovascular events (MACE)
Previous Post

COVID-19 pandemic associated with decreased emergency department access for sexual assaults

Next Post

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

RelatedReports

Cardiac mortality paradoxically lower during times of national cardiology conferences
Cardiology

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

March 24, 2023
Renal stones in women linked with increased risk of coronary heart disease
Nephrology

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

March 22, 2023
Gastric bypass surgery reduces cardio-metabolic risk factors
Emergency

Over-the-scope clips superior to standard treatment of nonvariceal upper GI bleeding

March 22, 2023
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Synergistic interaction between risk burden and genetics for atrial fibrillation development

March 21, 2023
Next Post
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

2 Minute Medicine Rewind November 23 – November 30, 2014

Vaccines for Zaire Ebola virus disease are safe and generate an immune response

Similar outcomes after supracervical vs. total hysterectomy

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options